A Worldwide Support Network For Chronic Myelogenous Leukemia
Archives
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- April 2007
- March 2007
- February 2007
- January 2007
- December 2006
- November 2006
- October 2006
- September 2006
- August 2006
- July 2006
- June 2006
- May 2006
- April 2006
- March 2006
- February 2006
- January 2006
- December 2005
- November 2005
- October 2005
- September 2005
- August 2005
- July 2005
- June 2005
- May 2005
- April 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
- July 2004
- June 2004
Recent Posts
- Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
- Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
- Chronic myeloid leukemia: mechanisms of blastic transformation.
- Successful Treatment of Esophageal Squamous Cell Carcinoma in a Patient with Fanconi Anemia
- Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study.
- Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
- Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
- Ring chromosome 18 abnormality in acute myelogenous leukemia: the clinical dilemma.
- A non-coding cationic lipid DNA complex produces lasting anti-leukemic effects.
- Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
- 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.
- Erythroid Induction of Chronic Myelogenous Leukemia K562 Cells Following Treatment with a Photoproduct Derived from the UV-A Irradiation of 5-Methoxypsoralen.
- Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.
- Possible Treatment Strategy For Aggressive Leukemias
- Regulation of myeloid leukaemia by the cell-fate determinant Musashi.